GoodRx (NASDAQ:GDRX) Trading Up 3.2%

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s share price was up 3.2% on Tuesday . The company traded as high as $6.76 and last traded at $6.76. Approximately 394,534 shares changed hands during mid-day trading, a decline of 75% from the average daily volume of 1,572,341 shares. The stock had previously closed at $6.55.

Analysts Set New Price Targets

A number of analysts have recently weighed in on GDRX shares. Wells Fargo & Company upgraded shares of GoodRx from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $7.50 to $10.00 in a research note on Monday, March 25th. Royal Bank of Canada boosted their price objective on shares of GoodRx from $7.00 to $8.00 and gave the stock a “sector perform” rating in a research note on Friday, March 1st. The Goldman Sachs Group boosted their price objective on shares of GoodRx from $6.50 to $7.50 and gave the stock a “neutral” rating in a research note on Friday, March 1st. TD Cowen upped their target price on shares of GoodRx from $12.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, March 1st. Finally, UBS Group upped their target price on shares of GoodRx from $5.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, GoodRx has a consensus rating of “Hold” and an average price target of $8.78.

GoodRx Trading Down 0.3 %

The company has a market cap of $2.57 billion, a price-to-earnings ratio of -324.84, a PEG ratio of 3.57 and a beta of 1.42. The company has a debt-to-equity ratio of 0.85, a quick ratio of 7.12 and a current ratio of 7.12. The business’s 50 day moving average price is $6.88 and its 200-day moving average price is $6.19.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Thursday, February 29th. The company reported $0.02 earnings per share for the quarter, hitting the consensus estimate of $0.02. GoodRx had a negative net margin of 1.18% and a positive return on equity of 2.45%. The business had revenue of $196.64 million for the quarter, compared to analyst estimates of $195.59 million. On average, research analysts forecast that GoodRx Holdings, Inc. will post 0.23 EPS for the current year.

Institutional Investors Weigh In On GoodRx

Several large investors have recently made changes to their positions in GDRX. Tower Research Capital LLC TRC grew its holdings in shares of GoodRx by 2,602.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,919 shares of the company’s stock worth $39,000 after purchasing an additional 6,663 shares during the last quarter. Ensign Peak Advisors Inc bought a new stake in shares of GoodRx in the 3rd quarter worth about $42,000. Citigroup Inc. grew its holdings in shares of GoodRx by 301.7% in the 3rd quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock worth $45,000 after purchasing an additional 6,006 shares during the last quarter. Creative Planning bought a new stake in GoodRx during the 4th quarter worth about $50,000. Finally, Quadrature Capital Ltd bought a new stake in GoodRx during the 3rd quarter worth about $58,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.